Serdexmethylphenidate (99.55 % purity) and dexmethylphenidate (99.70 % purity) were kindly provided by Novartis Pharma S.A.E., Cairo, Egypt. Azstarys capsules (batch number R-11052) manufactured by Novartis Pharma S.A.E., Cairo, Egypt, under license from Novartis Consumer Health SA—Switzerland; labeled to contain 52.3 mg of Serdexmethylphenidate and 10.4 mg dexmethylphenidate per capsule. Acetonitrile, dichloroethane and methanol, all of HPLC grade (Sigma-Aldrich, Germany). Hydrochloric acid and Sodium hydroxide, analytical grade (El-Nasr Co., Egypt), were prepared as 0.1N aqueous solutions. Phosphate buffer (pH 5.5) was prepared.
Dexmethylphenidate
Manufactured by Novartis
Sourced in Egypt, Switzerland
Dexmethylphenidate is a pharmaceutical product used for laboratory research and testing. It is the active enantiomer of methylphenidate, a central nervous system stimulant. Dexmethylphenidate is commonly used in various scientific studies and experiments.
Automatically generated - may contain errors
1 protocol using dexmethylphenidate
1
Serdexmethylphenidate and Dexmethylphenidate Analysis
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!